Tag:
Cerulean Pharma
Latest Headlines
Latest Headlines
Cerulean garners $15M for PhII lung cancer study
Cambridge, MA-based Cerulean Pharma --a 2011 Fierce 15 company --has banked a $15 million D round from a long lineup of venture backers avid to finance the biotech's Phase II study of its lead drug for
Cerulean Pharma enrolling for Phase 2 lung cancer trial
Cerulean Pharma is moving on to a Phase 2 clinical trial of its new lung cancer drug, CRLX101, boosted by early clinical results suggesting that the treatment is well-tolerated and possibly stops the...
Lilly Ventures leads $24M round for Cerulean's PhII
With a big assist from Eli Lilly's ( $LLY ) venture arm, Cambridge, MA-based Cerulean Pharma has rounded up $24 million in Series C cash. The money will be used to fuel a mid-stage trial of its lead
Cerulean pockets $10M as it catapults into the clinic
With the ink still drying on a new deal to license in nanoparticle technology developed by Calando Pharmaceuticals, Cerulean Pharma is set to announce later this morning that it has gone back to the
Calando inks licensing deal with Cerulean
Calando Pharmaceuticals, a subsidiary of Arrowhead Research, has struck a licensing deal with Cerulean Pharma for Calando's drug delivery platform, Cyclosert, and the associated clinical stage
